---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-21-003507"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:10:12.688462+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Chemomab reports Q3 net loss of $3.0M; cash $64.3M; appoints new CEO and CFO

## Summary
- Cash and equivalents $64.3M as of Sept 30, 2021; expected to fund operations to mid-2023.
- Net loss for Q3 2021 of $3.0M ($0.01/share) vs $1.2M loss in Q3 2020.
- R&D expenses $1.5M (up from $1.0M); G&A $1.4M (up from $0.2M) due to public company costs and share-based comp.
- Appointed Dale Pfost as CEO and Donald Marvin as CFO/COO; progressing three Phase 2 trials.
- Phase 2 data readouts expected: liver fibrosis H1 2022, PSC H2 2022; SSc trial starts early 2022.

## SEC filing metadata
- accession: 0001178913-21-003507
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003507/0001178913-21-003507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003507/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-21-003507
- JSON: https://secwatch.observer/filing/0001178913-21-003507.json
- Plain text: https://secwatch.observer/filing/0001178913-21-003507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.